Accelerated development of the dual orexin receptor antagonist ACT-541468: Integration of a microtracer in the first-in-human study.
4 May 2018. doid: 10.1002/cpt.1046
Muehlan C, Heuberger J, Juif PE, Croft M, van Gerven J, Dingemanse J
View publicationThe orexin system regulates sleep and arousal and is targeted by ACT-541468, a new dual orexin receptor antagonist (DORA). Healthy male subjects received a single oral dose of 5-200 mg, to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), mass balance, metabolism, and absolute bioavailability utilizing aC-labeled, orally and intravenously (i.v) administered microtracer. The drug was safe and well tolerated; the PK profile was characterized by quick absorption and elimination, with median time to reach maximum concentration (t) of 0.8-2.8 h and geometric mean terminal half-life (t) of 5.9 to 8.8 h. Clear dose-related effects on the central nervous system (CNS) were observed at ≥ 25 mg, indicating a suitable PK-PD profile for a sleep-promoting drug, allowing for rapid onset and duration of action limited to the intended use. This comprehensive first-in-humans (FIH) study created a wealth of data while saving resources in drug development. This article is protected by copyright. All rights reserved.
Advancing the boundaries of clinical drug development
Wondering how we can help you? Reach out to us.
